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Abstract
Tumor necrosis factor a (TNF-a) is a proinflammatory cytokine that induces apoptosis in a number of cell systems, including osteoblasts.
Transforming growth factor h1 (TGF-h1) is an abundant growth factor that is known to stimulate bone formation. This study was designed to
examine the role of TGF-h1 on TNF-a-induced apoptosis in murine osteoblastic MC3T3-E1 cells. Total RNA was extracted from MC3T3-
E1 cells treated with 20 ng/ml of TNF-a, 10 ng/ml of TGF-h1, or combination, for 6 h. TNF-a exerted a variety of effects on the apoptotic
gene expression in osteoblasts. Ribonuclease protection assays (RPA) revealed that TNF-a upregulated the mRNA levels of caspase-1, -7,
-11, -12, and FAS. Western blot analysis showed enhanced processing of caspase-1, -7, -11, and -12, with the appearance of their activated
enzymes 24 h after TNF-a treatment. In addition, caspase-3-like activity was significantly activated following TNF-a treatment. Levels of
cleaved poly(ADP–ribose) polymerase and FAS protein were also elevated by TNF-a. Finally, Hoechst staining, terminal deoxynucleotidyl-
transferase nick-end labeling (TUNEL) assay, and oligonucleosome ELISA all indicated that TNF-a induced apoptosis. In contrast, the
addition of TGF-h1 attenuated all of the aforementioned effects of TNF-a. Our results demonstrate that TGF-h1 can decrease TNF-a-
induced apoptosis in murine osteoblasts at least in part by attenuating TNF-a-induced caspase gene expression.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis is crucial for a number of processes including
development, tissue homeostasis, viral infection, and cancer
[1–3]. It is characterized by cell shrinkage, membrane
blebbing, chromatin condensation, and nuclear DNA deg-
radation. Caspases, cysteine proteases with aspartate specif-
icity, are important mediators of apoptosis. The activation of
caspases arises from a number of mechanisms including
transcriptional activation, regulation of IAP proteins, auto-
activation, or cleavage by other caspases [4–6]. To date,
14 members of the caspase family have been isolated.
They can be categorized into three groups [7]: initiator
caspases (-8, -9, and -10), effector caspases (-3, -6, and -7),
and inflammation caspases (-1 and -11).
Bone turnover is controlled by two main types of cells,
osteoblasts and osteoclasts, which are responsible for bone
formation and resorption, respectively [8,9]. Accumulating
evidence indicates that apoptosis plays a central role in the
regulation of bone turnover [10,11]. In fact, Jilka et al. [12]
demonstrated that apoptosis is the main fate for most
osteoblasts. Because bone diseases such as osteoporosis
can be caused by a relatively decreased activity or reduced
numbers of osteoblasts, prevention of osteoblast apoptosis
can be an extremely important clinical goal.
Numerous cytokines and growth factors are present in
the bone environment; some are pro-apoptotic, while others
are anti-apoptotic [13]. Tumor necrosis factor a (TNF-a), a
proinflammatory cytokine secreted by monocytes, plays a
key role in abnormal bone remodeling and inflammatory
bone diseases [14]. Importantly, it is a potent inducer of
apoptosis in osteoblasts [15,16]. TNF-a induces apoptosis
by interacting with its receptors (TNF-R1 and TNF-R2) and
death receptors such as FAS [17,18]. The roles of specific
caspases and TNF-receptor-related proteins in TNF-a-in-
duced apoptosis in osteoblasts are not clearly understood.
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Transforming growth factor h1 (TGF-h1) is an abundant
growth factor produced by a number of cells including
osteoblasts [19]. It stimulates the synthesis of extracellular
matrix components such as fibronectin, collagen, osteonec-
tin, and integrins [20,21]. Administration of TGF-h1 has
been reported to enhance cancellous bone formation in
juvenile and adult rat bone and fracture healing [22,23].
TGF-h1 has been shown to regulate apoptosis in osteoblasts
[12]. However, the molecular basis for the protective effect
has not been determined in any detail.
In this report, we studied the involvement of caspases
and TNF-receptor proteins in TNF-a-induced apoptosis and
examined if TGF-h1 exerts its effect by counteracting TNF-
a in murine osteoblastic MC3T3 cells. We found that TNF-
a induced apoptosis in murine osteoblastic MC3T3-E1 cells
by upregulating FAS expression and by activating caspase-
1, -3, -7, -11, and -12. Furthermore, the addition of TGF-h1
attenuated the effects of TNF-a. Our results indicate that
TGF-h1 is a potent inhibitor of TNF-a-induced apoptosis in
osteoblasts.
2. Materials and methods
2.1. Cell culture and materials
Murine osteoblastic MC3T3-E1 cells were cultured in a-
modified MEM (Sigma, St. Louis, MO) containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine, and 25 Ag/ml
gentamicin at 37 jC in a humidified atmosphere of 5% CO2.
Cells were serially subcultured by treatment with trypsin
and were used for experimentation between passages 5 and
15. Human recombinant TNF-a and TGF-h1 were pur-
chased from R&D Systems (Minneapolis, MN). a-
[32P]UTP was obtained from ICN (Costa Mesa, CA). Fetal
bovine serum was obtained from Biofluid Division-Bio-
source International (Rockville, MD). Mouse apoptosis
gene templates mAPO1, mAPO2, and mAPO3 were
obtained from BD Pharmingen (San Diego, CA). Caspase-
1 antibody was purchased from Upstate Biotechnology
(Lake Placid, NY). FAS antibody was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Caspase-7, cleaved
caspase-9, and cleaved PARP antibodies were obtained from
Cell Signaling Technology (Beverly, MA). Rat monoclonal
caspase-11 and -12 antibodies were generous gifts from Dr.
Junying Yuan of Harvard Medical School. Mouse mono-
clonal actin antibodies (clone AC-40) were purchased from
Sigma. Caspase-3 cellular activity assay kit was obtained
from Biomol (Plymouth Meeting, PA).
2.2. RPA
MC3T3-E1 cells were seeded into 100-mm dishes con-
taining a-MEM supplemented with 10% FBS. Near con-
fluent cells were changed to a-MEM containing 0.5% FBS
for 16 h before the addition of 20 ng/ml of TNF-a, 10 ng/ml
of TGF-h1, or both, for 6 h. Total RNAwas extracted using
acid guanidinium thiocyanate–phenol–CHCl3 extraction
method. RPA was performed according to manufacturer’s
instructions (BD Pharmingen). Briefly, murine apoptosis
template sets mAPO-1 (caspases 1, 2, 3, 6, 7, 8, 11, 12,
and 14), mAPO-2 (bcl-w, bfl1, bcl-x, bak, bax, bcl-2, bad),
and mAPO-3 (caspase 8, FAS L, FAS, FADD, FAP, FAF,
TRAIL, TNFRp55, TRADD, RIP) were labeled with
[a-32P]UTP. RNA (10 Ag) and labeled probes were hybri-
dized and the protected mRNAs were resolved on a 5%
denaturing polyacrylamide gel. Intensity of the band was
scanned by a Digital Imaging System (Alpha Innotech, San
Leandro, CA).
2.3. Western blot analysis
Near confluent MC3T3-E1 cells in 100-mm dishes were
incubated with a-MEM containing 0.5% FBS for 16 h
before treatment with TNF-a, TGF-h1, or both, for 24 h.
Cells were lysed in 2 SDS gel sample buffer and
sonicated. Protein concentration was determined by Coo-
massie dye binding assay (BioRad, Hercules, CA). Aliquots
of 50 Ag of lysates were electrophoresed on 12% SDS-
PAGE and transferred to nitrocellulose membranes. Western
blot analysis was carried out with antibodies against cas-
pase-1, -7, -11, -12, cleaved PARP, FAS, and actin. Appro-
priate secondary antibody conjugated to horseradish
peroxidase was then added for 1.5 h. Antigen–antibody
complex was detected using enhanced chemiluminescence
reagent (Amersham Pharmacia Biotech, Piscataway, NJ).
Intensity of the band was subjected to image analysis.
2.4. Caspase-3-like activity assay
Near confluent MC3T3-E1 cells in 100-mm dishes were
incubated with a-MEM containing 0.5% FBS for 16 h
before treatment with TNF-a, TGF-h1, or both, for 24 h.
Cells were lysed with a buffer containing 50 mM Hepes, pH
7.4, 0.1% CHAPS, 0.1% NP-40, 5 mM DTT, 0.1 mM
EDTA at 4 jC for 20 min. Protein concentration was
determined by Coomassie dye binding assay. Cell homoge-
nate containing 40 Ag of proteins was assayed for caspase-3-
like activity in the presence of 200 AM colorimetric sub-
strate Ac-DEVD-pNA at 37 jC for 4 h according to
manufacturer’s protocol. An aliquot of cell lysate was
treated with 0.1 AM of inhibitor Ac-DEVD-CHO to measure
the nonspecific hydrolysis of Ac-DEVD-pNA. Human cas-
pase-3 was included as a positive control. Results were
expressed as absorbance at 405 nm/mg protein.
2.5. Hoechst stain
Near confluent MC3T3-E1 cells on 12-mm coverslips
(precoated with 0.01% poly L-lysine) were incubated with
a-MEM containing 0.5% FBS for 16 h before treatment
with TNF-a, TGF-h1, or both, for 24 h. Cells were fixed
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with 4% paraformaldehyde for 30 min and stained with 10
Ag/ml of Hoechst 33258 dye at room temperature for 10
min. After extensive washing, cells were examined under a
microscope equipped for epifluorescence illumination.
2.6. Terminal deoxynucleotidyl-transferase nick-end label-
ing (TUNEL) assays
TUNEL assay was performed with an in situ apoptosis
detection kit (Trevigen, Gaithersburg, MD) according to
manufacturer’s instructions with minor modifications.
Briefly, cells on 12-mm coverslips were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-
100 in phosphate buffered saline on ice for 5 min before
TUNEL staining. In this procedure, nuclei undergoing
apoptosis were stained with TACSk Blue Label chromo-
genic substrate, and Nuclear Fast Red was used as a
counterstain. Positive and negative controls were carried
Fig. 2. Message levels of TNF-receptor family proteins in MC3T3-E1 cells.
RNAwas extracted from MC3T3-E1 cells treated with TNF-a, TGF-h1, or
both, for 6 h. RPAwas performed with mAPO3 template set as described in
the Materials and methods. Lower panel shows shorter exposure of L32 and
GAPDH bands. The results are representative of six separate experiments.
Table 1
Fold induction of mRNA levels
TNF-a TGF-h1 TNF-a+TGF-h1
Caspase-1 2.7F 0.3 1.1F 0.2a 1.1F 0.2b
Caspase-7 1.7F 0.1 1.0F 0.1a 1.0F 0.2b
Caspase-11 5.6F 0.8 1.8F 0.3a 3.7F 0.5b,c
Caspase-12 2.2F 0.2 1.0F 0.2a 1.0F 0.1b
FAS 4.0F 1.2 1.3F 0.2a 2.7F 1.1b
FAP 2.3F 0.3 0.8F 0.3a 0.8F 0.2b
Fold induction of mRNAwas determined by scanning the pixel intensity of
each band vs. the control level. GAPDH mRNA band was used to
normalize the differences in loading. Data represent meanF SE of six
samples.
a P < 0.05, TNF-a vs. TGF-h1.
b P < 0.05, TNF-a vs. TNF-a +TGF-h1.
c P < 0.05, TGF-h1 vs. TNF-a+TGF-h1.
Fig. 1. Caspase mRNA expression in MC3T3-E1 cells. RNAwas extracted
from MC3T3-E1 cells treated with TNF-a, TGF-h1, or both, for 6 h. RPA
was performed with mAPO1 template set as described in the Materials and
methods. The specific mRNA transcripts are labeled using the nomencla-
ture from the supplier. Lower panel shows shorter exposure of L32 and
GAPDH bands. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. The
results are representative of six separate experiments.
C.C. Chua et al. / Biochimica et Biophysica Acta 1593 (2002) 1–8 3
out by DNase I treatment and by omitting TdT from the
labeling mix, respectively.
2.7. Cell death ELISA
Quantitative analysis of apoptosis was performed with a
Cell Death ELISAPlus kit (Roche, Indianapolis, IN). Cells
(3 104) were plated in 48-well dishes, changed to a-MEM
containing 0.5% FBS for 16 h, and treated with TNF-a,
TGF-h1, or both, for 24 h. Cells were lysed with 0.2-ml
lysis buffer at room temperature for 45 min. Quantities of
histone-associated DNA fragments (mononucleosomes and
oligonucleosomes) were determined at 405 nm with a
microplate ELISA reader.
2.8. Statistical analysis
Statistical analyses were performed by one-way ANOVA
followed by Tukey’s multiple comparison test to show differ-
ences between means. Data were represented as meansF SE.
P < 0.05 was considered significant.
3. Results
Our first set of experiments was designed to study levels
of mRNA transcripts of numerous apoptosis-regulating
genes by RPA. Three commercially available gene templates
were obtained from BD Pharmingen: mAPO-1 (caspase
family), mAPO-2 (Bcl-2 family), and mAPO-3 (TNF-recep-
tor family). Treatment of MC3T3-E1 cells with TNF-a for 6
h upregulated the mRNA levels of caspase-1, -7, -11, and
-12, whereas the mRNA levels of caspase-2, -3, -6, -8, and
-14 remained unchanged (Fig. 1). When TGF-h1 was added
in combination with TNF-a, this induction was decreased.
In addition to its effects on the aforementioned caspases,
TNF-a also significantly upregulated the mRNA levels of
FAS and FAP (Fig. 2). This upregulation, as with the
caspases, was suppressed by TGF-h1 (Fig. 2). FADD,
TRAIL, and RIP mRNA levels were only slightly increased
by TNF-a, whereas FAF, TNFRp55, and TRADD levels did
not change. In these experiments, L32 and GAPDH served
as loading controls. Table 1 summarizes a quantitative
analysis of the magnitude of induction for these four
caspases, FAS and FAP. Neither TNF-a nor TGF-h1 had
Fig. 3. Western blot analysis of apoptotic proteins. MC3T3-E1 cells were
treated with or without TNF-a, TGF-h1, or both, for 24 h. Western blot
analysis was carried out with antibodies specific for caspase-1, -7, -11, -12,
cleaved PARP, FAS, and actin. Antibody against actin demonstrates equal
loading of proteins. Data represent three separate experiments.
Fig. 4. Effects of TNF-a or TGF-h1 on caspase-3-like activity in MC3T3-
E1 cells. Caspase-3-like activity was measured by the proteolytic cleavage
of colorimetric substrate Ac-DEVD-pNA as described in the Materials and
methods. Experiments were carried out three separate times. Data represent
meanF SE of four samples. a =P < 0.05 vs. CON, b =P< 0.05 vs. TNF-a
treatment.
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any apparent effect on the transcript levels of mAPO2
genes, including bcl-w, bfl 1, bcl-x, bak, bax, bcl-2, and
bad (results not shown).
To investigate the expression of caspases at the protein
level, lysates were prepared from cells treated with TNF-a,
TGF-h1, or both, for 24 h. Caspase-1 was present as 45-,
36-, 32-, and 20-kDa bands in untreated cells. After 24-h
exposure to TNF-a, all bands were enhanced in intensity.
The smaller fragments of 36, 32, and 20 kDa represented the
cleavage products of 45-kDa procaspase-1 (Fig. 3). All
fragments were decreased when TGF-h1 was added along
with TNF-a. In addition, procaspase-7 was detected as a 35-
kDa band in untreated cells. After TNF-a treatment, the 35-
kDa band increased in intensity with a concomitant appear-
ance of the activated 20-kDa large subunit. Aswith caspase-1,
TGF-h1 attenuated the activation of caspase-7 (Fig. 3).
Procaspase-11 was barely detectable in untreated cells.
After TNF-a treatment, the two procaspase-11 bands (43 and
Fig. 5. Nuclear staining by Hoechst stain and identification of DNA fragmentation by TUNEL assays. MC3T3-E1 cells were treated with or without TNF-a,
TGF-h1, or both, for 24 h. Panels A–D show Hoechst staining patterns of cells from (A) control, (B) TNF-a , (C) TGF-h1, and (D) TNF-a +TGF-h1. Panels
E–H represent TUNEL staining patterns of cells from (E) control, (F) TNF-a, (G) TGF-h1, and (H) TNF-a+TGF-h1. TUNEL-positive nuclei were stained
blue. These experiments were carried out three times.
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38 kDa) appeared along with a 30-kDa fragment. In the
presence of TNF-a and TGF-h1, these two procaspase bands
and the 30-kDa fragment decreased in intensity (Fig. 3).
Caspase-12 was present as 60- and 54-kDa bands in untreated
cells. Upon TNF-a treatment, these two bands were intensi-
fied with a concomitant appearance of a 36-kDa band. The
addition of TGF-h1 abrogated the induction (Fig. 3).
Poly(ADP–ribose) polymerase is a substrate for caspase-3
and -7 [24] and cleaved PARP has been shown to be an
important marker for apoptosis [25]. We next determined
PARP levels in cell lysates with a monoclonal antibody that
was specific to the 89-kDa cleaved PARP. TNF-a treated cells
had a marked increase of cleaved PARP, while the addition of
TGF-h1 suppressed its level (Fig. 3). FAS, a member of the
TNF receptor family, is a 45-kDa membrane protein [24].
FAS was strongly induced by TNF-a and the induction was
diminished in the presence of TGF-h1 (Fig. 3).
Our RPA results did not show any change of caspase-3
mRNA level (Fig. 1). Since caspase-3 is a ubiquitous
caspase that is often activated during apoptosis, we set out
to examine if caspase-3 activity was elevated as a result of
TNF-a treatment. Caspase-3-like activity was measured by
the proteolytic cleavage of colorimetric substrate Ac-
DEVD-pNA. Fig. 4 shows caspase-3-like protease activity
was significantly increased 24 h after TNF-a treatment,
whereas TGF-h1 could attenuate the activation. It is noted
that caspase-3-like activity in TGF-h1-treated cells was
lower than that of the control cells. Western blot analysis
showed an induction of active caspase-3 by TNF-a and
inhibition by TGF-h1. However, this induction was not as
obvious as it was with caspase-1, -7, -11, and -12 (results
not shown).
Since the gene template used in our RPA studies (Fig. 1)
did not contain caspase-9, Western blot analysis was carried
out with an antibody specific to cleaved caspase-9 to
examine if TNF-a affected the processing of caspase-9.
Our results showed no changes of caspase-9 pattern as a
result of TNF-a or TGF-h1 treatment (data not shown).
Experiments were performed to determine if TGF-h1
could attenuate TNF-a-induced apoptosis in murine osteo-
blasts. DNA fragmentation was assessed by three methods:
Hoechst staining, TUNEL assay, and cell death ELISA.
Hoechst staining of cells treated with TNF-a showed typical
pyknotic fragmented nuclei and apoptotic bodies (Fig. 5,
panel B). In addition, cells treated with TGF-h1 showed few
condensed nuclei (panel C), and the addition of TGF-h1
along with TNF-a reduced the number of apoptotic nuclei
(panel D). Similar results were obtained with TUNEL
assays. Treatment with TNF-a resulted in an extensive
increase in the number of TUNEL-positive blue nuclei
(panel F), while combined treatment of TGF-h1 and TNF-
a significantly reduced the number of TUNEL-positive
nuclei (panel H).
Finally, quantitation of apoptosis was performed by an
oligonucleosomal cell death ELISA assay. As shown in Fig.
6, TNF-a increased cell death by 2.7-fold, an increase that
was attenuated by the addition of TGF-h1. In this assay, we
also noted that the oligonucleosomal formation in TGF-h1-
treated cells was lower than the control.
4. Discussion
In this study, we show that TNF-a induces apoptosis in
murine osteoblastic MC3T3-E1 cells by upregulating FAS
expression and by activating caspase-1, -3, -7, -11, and -12.
Furthermore, we also present evidence that TGF-h1 can
decrease the apoptotic process by attenuating the expression
of these apoptotic proteins. These findings support the work
of Jilka et al. [12] who previously reported that TGF-h1 and
interleukin-6 were able to inhibit TNF-a-induced apoptosis
in murine osteoblastic MC3T3-E1 cells. However, our study
expands on this previous work by exploring the involve-
ment of various caspases pertaining to the effects of TNF-a
and TGF-h1 on apoptosis.
FAS–FAS ligand system is a major pathway for the
induction of apoptosis [26]. Our RPA results showed that
the addition of TNF-a led to an upregulation of FAS mRNA
expression by fourfold (Fig. 2) as well as the induction of
FAS protein (Fig. 3), suggesting that TNF-a-induced apop-
tosis is partly mediated by the upregulation of FAS. Our
results agreed with previous reports that TNF-a induces
FAS in human osteoblasts [27,28].
Caspase-1, -4, -5, -11, -12, and -13 belong to caspase-1
subfamily. The present study shows that TNF-a upregulates
three of the six members of the caspase-1 subfamily:
caspase-1, -11, and -12. Caspase-1, which functions both
as an initiator caspase and as an effector caspase, is the best
characterized enzyme in this subfamily and is known to play
a major role in inflammation and immune regulation in
addition to apoptosis [29,30].
Fig. 6. Quantitative analysis of DNA fragmentation. MC3T3-E1 cells in 48-
well dishes were treated with TNF-a, TGF-h1, or both, for 24 h. Cell
lysates were subjected to Cell Death ELISA assay. Oligonucleosomes were
measured at 405 nm by a microplate reader. Experiments were carried out
three separate times. Data represent meanF SE of eight samples. a =
P < 0.05 vs. CON, b =P< 0.05 vs. TNF-a treatment.
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Our results demonstrated that TNF-a treatment induced
the expression of caspase-11 mRNA 5.6-fold (Fig. 1).
These results support previous studies that caspase-11 is
crucial for apoptosis. Wang et al. [31] showed that cas-
pase-11 knockout mice had impaired production of inter-
leukin-1h and caspase-1 mediated apoptosis, indicating
that caspase-11 is important for both inflammation and
apoptosis. In addition to its role in activating caspase-1,
caspase-11 also activates caspase-3 under pathological con-
ditions [32].
To our knowledge, we demonstrate for the first time that
caspase-12 is upregulated by TNF-a in osteoblasts. Procas-
pase-12 is predominantly localized at the ER and is acti-
vated by ER stress such as disruption of ER calcium
homeostasis or accumulation of excess protein in ER [33].
Yoneda et al. [34] reported that caspase-12 is activated
through a TNF-receptor-associated factor 2 (TRAF-2)-
dependent mechanism in response to ER stress. Since
caspase-12 is a newly discovered enzyme, its relationship
with other caspases is not clear. It remains to be determined
whether caspase-12 functions as an initiator caspase, an
effector caspase, or both.
A unique finding of this study is that both caspase-3 and
caspase-7 are specifically activated by TNF-a in osteoblasts.
Caspase-7 shares 54% sequence homology with caspase-3,
and it can be activated by caspase-3, -8, and -10 [35].
Caspase-7 and caspase-3 are effector caspases that are
responsible for cleaving nucleases in addition to cellular
substrates including lamins and PARP. A recent study has
indicated that caspase-7 is also required for the activation of
caspase-12 as a result of ER stress [36].
It should be noted that TGF-h1 treated cells had lower
caspase-3-like activity (Fig. 4) and DNA fragmentation than
the control cells (Fig. 6). It is possible that the control cells
produce TNF-a and the inhibitory effects of TGF-h1 alone
on apoptosis might be due to an autocrine loop of TNF-a.
The inhibition of caspase production by TGF-h1 could be
mediated by induction of inhibitors of apoptosis (IAPs) or
anti-apoptotic Bcl2 family members. Alternatively, TGF-h1
may activate PI3K-Akt pathways. The exact mechanism
awaits further investigation.
The protective role of TGF-h1 has been demonstrated in
a number of studies. For example, TGF-h1 has been shown
to protect mature osteoblasts from apoptosis [37]. Recently,
TGF-h2, a growth factor similar to TGF-h1, was found to
inhibit apoptosis in primary human osteoblasts or immor-
talized human osteoblasts [38]. In addition, TGF-h1 inhibits
FAS-mediated apoptosis in T lymphocytes and rheumatoid
synovial cells [39]. The protective mechanism of TGF-h1
warrants further investigation.
In summary, we found that TNF-a induced apoptosis by
upregulating caspase-1, -3, -7, -11, -12, and FAS in MC3T3-
E1 cells; these effects can be attenuated by the addition of
TGF-h1. TGF-h1 may eventually be utilized as a potential
therapeutic agent to treat TNF-a-induced osteoporosis in
rheumatoid arthritis and periodontal disease.
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